Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization

Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization

In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.

Gardado en:
Detalles Bibliográficos
Main Authors: Jie Zheng, Eleanor Wheeler, Maik Pietzner, Till F. M. Andlauer, Michelle S. Yau, April Hartley, Ben Brumpton, Humaira Rasheed, John P. Kemp, Monika Frysz, Jamie Robinson, Sjur Reppe, Vid Prijatelj, Kaare M. Gautvik, Louise Falk, Winfried Maerz, Ingrid Gergei, Patricia A. Peyser, Maryam Kavousi, Paul S. de Vries, Clint L. Miller, Maxime M. Bos, Sander W. van der Laan, Rajeev Malhotra, Markus Herrmann, Hubert Scharnagl, Marcus E. Kleber, George Dedoussis, Eleftheria Zeggini, Maria Nethander, Claes Ohlsson, Mattias Lorentzon, Nicholas J. Wareham, Claudia Langenberg, Michael V. Holmes, George Davey Smith, Jonathan H. Tobias
Formato: Revisão
Idioma:inglés
Publicado: 2023
Acceso en liña:https://doi.org/10.1002/art.42538
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Internet

https://doi.org/10.1002/art.42538

Títulos similares